Institute of Genomics and Integrative Biology (IGIB), constituent lab of CSIR, has signed a MoU with TATA Sons for licensing of KNOWHOW for FELUDA in order to execute rapid diagnosis of COVID-19. The MoU aims to provide license which will enable transfer of the knowledge for scaling up the KNOWHOW in the form of a kit in order to employ it for COVID-19 testing on ground as soon as possible. Hence, as per MoU, CSIR-IGIB will now work along with TATA Sons to bring FELUDA for widespread use at the earliest.
Click Here To Get Test Series For SBI PO 2020
FNCAS9 Editor Linked Uniform Detection Assay (FELUDA) has been designed to alleviate the current COVID-19 situation and cater to mass testing. The main advantages of FELUDA is its affordability, relative ease of use as well as non-dependency on expensive Q-PCR machines.
In a landmark move to promote gender equality and improve the welfare of personnel, Defence…
The Bihar Student Credit Card Scheme (BSCC) is a flagship program under the Department of…
State Bank of India (SBI) is set to become the first Indian bank in 2026…
India’s financial technology ecosystem witnessed two significant developments in July 2026, with Axis Finance Limited…
National flags are known to be the most reputed symbols representing a nation’s identity, history,…
The Reserve Bank of India (RBI) has announced that the operations of Paytm Payments Bank…